Express Pharma
Home  »  Latest Updates  »  DRL continues to recall Levetiracetam injection from US market

DRL continues to recall Levetiracetam injection from US market

8

The recall, which began in October 2018, was originally initiated due to a product complaint received for mislabelling

Dr Reddy’s Laboratories (DRL) announced its wholly-owned subsidiary in the US is continuing its voluntary nation-wide recall of lot ABD807 of Levetiracetram in 0.54 per cent Sodium Chloride injection, 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags to the hospital level in the North American country.

According to a letter written to the US Food and Drug Administration on Februray 4, the drug maker said the recall, which began in October 2018, was originally initiated due to a product complaint received for mislabelling.

“The pre-printed text content on the infusion bag (primary container) for the lot indicates product information as Levetiracetam in 0.75 per cent Sodium Chloride injection (1,000mg/100mL). The label on the external foil pouch has the product information as Levetiracetam in 0.54 per cent Sodium Chloride Injection (1,500mg/100mL). To date, there have been no reports of adverse events related to this recall,” DRL said.

Levetiracetam injection is an anti-epileptic drug indicated for adjunct therapy in adults on certain types of seizures when oral administration is temporarily not feasible. Patients who may have been administered the mislabelled product could experience adverse reactions such as somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma related to overdosage, it said. The batch was distributed in the US between August 14, 2018 and September 5, 2018.

DRL has notified the distributors to arrange for return of any recalled product. Wholesalers, distributors, hospitals and pharmacies with an existing inventory of the lot being recalled, should stop use and distribution and quarantine the product immediately for return/replacement of all recalled products, the drug maker said.

Comments are closed.